ArticleMediterranean journal of rheumatology2025
Managing Yao Syndrome: A Case of Beneficial Treatment with Upadacitinib and Leflunomide.
Article in Mediterranean journal of rheumatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Multi-omics characterization of Yao syndrome identifies three pathophysiological axes and disease-specific divergence from Blau syndrome.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2026Article
- NOD2-Related Multisystem Inflammatory Disorders and Recent Advances.Current rheumatology reports · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Yao syndrome, an autoinflammatory disease associated with specific NOD2 gene variants, presents with a wide range of symptoms, including fever, dermatitic rashes, polyarthritis, abdominal pain/bloating, and sicca symptoms. The initial clinical manifestation remains widely variable. The first-line treatment options remain unknown due to limited knowledge of the pathophysiology and the absence of robust literature. We report a case of a 36-year-old woman diagnosed with Yao syndrome, presenting with postprandial bloating, followed by polyarthralgia and low-grade fever. After experiencing reactions to treatments, including anaphylaxis secondary to anakinra and canakinumab, the patient showed improvement with upadacitinib and leflunomide, resulting in better control of her symptoms.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.